Second attempt to withdraw cabergoline in prolactinomas: a pilot study

被引：0
|
作者：
Ratchaneewan Kwancharoen
Renata Simona Auriemma
Gayane Yenokyan
Gary S. Wand
Annamaria Colao
Roberto Salvatori
机构：
[1] Johns Hopkins University School of Medicine,Division of Endocrinology and Metabolism, Department of Medicine, Pituitary Center
[2] Johns Hopkins University School of Public Health,Department of Biostatistics
[3] University “Federico II”,Sezione di Endocrinologia, Dipartimento di Medicina Clinica e Chirurgia
来源：
Pituitary | 2014年 / 17卷
关键词：
Cabergoline; Prolactinoma; Second withdrawal; Recurrence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：451 / 456
页数：5
相关论文
共 50 条
  • [21] Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
    Huang, Hai Yan
    Zhai, Weiwei
    Tang, Hao
    Hui, Guo Zhen
    Wu, Zhe Bao
    ENDOCRINE, 2018, 62 (02) : 464 - 469
  • [22] Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline
    Verhelst, JA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12): : 4747 - 4747
  • [23] Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
    Hai Yan Huang
    Weiwei Zhai
    Hao Tang
    Guo Zhen Hui
    Zhe Bao Wu
    Endocrine, 2018, 62 : 464 - 469
  • [24] Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia
    Miki, N
    INTERNAL MEDICINE, 2001, 40 (09) : 845 - 846
  • [25] A pilot study of cabergoline for the treatment of metastatic breast cancer
    Ricardo Costa
    C. A. Santa-Maria
    D. M. Scholtens
    S. Jain
    L. Flaum
    W. J. Gradishar
    C. V. Clevenger
    V. G. Kaklamani
    Breast Cancer Research and Treatment, 2017, 165 : 585 - 592
  • [26] A pilot study of cabergoline for the treatment of metastatic breast cancer
    Costa, Ricardo
    Santa-Maria, C. A.
    Scholtens, D. M.
    Jain, S.
    Flaum, L.
    Gradishar, W. J.
    Clevenger, C. V.
    Kaklamani, V. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 585 - 592
  • [27] Audit of the prevalence of cardiac valvular abnormalities in patients treated with cabergoline for prolactinomas
    McKeever, E.
    Mullan, K. R.
    Johnston, N.
    Bell, P. M.
    Courtney, C. H.
    Hunter, S. J.
    McCance, D. R.
    Atkinson, A. B.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S504 - S504
  • [28] Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review
    Huang, Hai Yan
    Lin, Shao Jian
    Zhao, Wei Guo
    Wu, Zhe Bao
    METABOLIC BRAIN DISEASE, 2018, 33 (03) : 969 - 976
  • [29] Increased prevalence of tricuspid regurgitation in patients with Prolactinomas chronically treated with cabergoline
    Colao, Annamaria
    Galderisi, Maurizio
    Di Sarno, Antonella
    Pardo, Moira
    Gaccione, Maria
    D'Andrea, Marianna
    Guerra, Ermelinda
    Pivonello, Rosario
    Lerro, Giuseppe
    Lombardi, Gaetano
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10): : 3777 - 3784
  • [30] Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
    Colao, A
    DiSarno, A
    Sarnacchiaro, F
    Ferone, D
    DiRenzo, G
    Merola, B
    Annunziato, L
    Lombardi, G
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (03): : 876 - 883
12345